Table 1 Baseline patient characteristics
Non-NK1RA group | NK1RA group | |
|---|---|---|
(n = 31) | (n = 31) | |
Age, years | ||
Median (interquartile range) | 71 (67–76) | 71 (65–77) |
< 60 years | 2 (6.5%) | 2 (6.5%) |
≥ 60 years | 29 (93.5%) | 29 (93.5%) |
Sex | ||
Male | 18 (58.1%) | 18 (58.1%) |
Female | 13 (41.9%) | 13 (41.9%) |
ECOG performance status | ||
0 | 14 (45.2%) | 28 (90.3%) |
1 | 12 (38.7%) | 2 (6.5%) |
2 | 5 (16.1%) | 1 (3.2%) |
Cancer type | ||
Small-cell lung cancer | 9 (29.0%) | 8 (25.8%) |
Non-small-cell lung cancer | 17 (54.8%) | 14 (45.2%) |
Thymoma / thymic carcinoma | 5 (16.1%) | 0 (0.0%) |
Ovarian cancer | 0 (0.0%) | 4 (12.9%) |
Endometrial cancer | 0 (0.0%) | 4 (12.9%) |
Peritoneal cancer | 0 (0.0%) | 1 (3.2%) |
Planned carboplatin dose | ||
AUC 5 mg/mL/min | 21 (67.7%) | 21 (67.7%) |
AUC 6 mg/mL/min | 10 (32.3%) | 10 (32.3%) |
Additional anticancer drugs | ||
Paclitaxel | 3 (9.7%) | 9 (29.0%) |
Paclitaxel + Pembrolizumab | 1 (3.2%) | 0 (0.0%) |
Paclitaxel + Bevacizumab | 0 (0.0%) | 1 (3.2%) |
Paclitaxel + Bevacizumab + Atezolizumab | 2 (6.5%) | 0 (0.0%) |
Nab-Paclitaxel | 0 (0.0%) | 3 (9.7%) |
Nab-Paclitaxel + Pembrolizumab | 3 (9.7%) | 0 (0.0%) |
Pemetrexed | 7 (22.6%) | 6 (19.4%) |
Pemetrexed + Pembrolizumab | 2 (6.5%) | 0 (0.0%) |
Pemetrexed + Bevacizumab | 0 (0.0%) | 2 (6.5%) |
Etoposide | 8 (25.8%) | 8 (25.8%) |
Etoposide + Atezolizumab | 2 (6.5%) | 0 (0.0%) |
Vinorelbine | 2 (6.5%) | 0 (0.0%) |
S-1 | 1 (3.2%) | 2 (6.5%) |
Risk factor | ||
Habitual alcohol consumption | 19 (61.3%) | 10 (32.3%) |
Motion sickness | 25 (80.6%) | 2 (6.5%) |
Morning sickness | 3 (9.7%) | 7 (22.6%) |